Skip to main content

Research Repository

Advanced Search

Preventing Preterm Birth with Progesterone in Women with a Short Cervical Length from a Low-Risk Population: A Multicenter Double-Blind Placebo-Controlled Randomized Trial

van Os, Melanie A; van der Ven, A Jeanine; Kleinrouweler, C Emily; Schuit, Ewoud; Kazemier, Brenda; Verhoeven, Corine; de Miranda, Esteriek; van Wassenaer-Leemhuis, Aleid; Sikkema, J Marko; Woiski, Mallory; Bossuyt, Patrick; Pajkrt, Eva; de Groot, Christianne; Mol, Ben; Haak, Monique

Authors

Melanie A van Os

A Jeanine van der Ven

C Emily Kleinrouweler

Ewoud Schuit

Brenda Kazemier

Esteriek de Miranda

Aleid van Wassenaer-Leemhuis

J Marko Sikkema

Mallory Woiski

Patrick Bossuyt

Eva Pajkrt

Christianne de Groot

Ben Mol

Monique Haak



Abstract

Objective: The objective of this study was to evaluate the effectiveness of vaginal progesterone in reducing adverse neonatal outcome due to preterm birth (PTB) in low-risk pregnant women with a short cervical length (CL).

Study Design: Women with a singleton pregnancy without a history of PTB underwent CL measurement at 18 to 22 weeks. Women with a CL ≤ 30 mm received vaginal progesterone or placebo. Primary outcome was adverse neonatal outcome, defined as a composite of respiratory distress syndrome, bronchopulmonary dysplasia, intracerebral hemorrhage > grade II, necrotizing enterocolitis > stage 1, proven sepsis, or death before discharge. Secondary outcomes included time to delivery, PTB before 32, 34, and 37 weeks of gestation. Analysis was by intention to treat.

Results: Between 2009 and 2013, 20,234 women were screened. A CL of 30 mm or less was seen in 375 women (1.8%). In 151 women, a CL ≤ 30 mm was confirmed with a second measurement and 80 of these women agreed to participate in the trial. We randomly allocated 41 women to progesterone and 39 to placebo. Adverse neonatal outcomes occurred in two (5.0%) women in the progesterone and in four (11%) women in the control group (relative risk [RR], 0.47; 95% confidence interval [CI], 0.09–2.4). The use of progesterone resulted in a nonsignificant reduction of PTB < 32 weeks (2.0 vs. 8.0%; RR, 0.33; 95% CI, 0.04–3.0) and < 34 weeks (7.0 vs. 10%; RR, 0.73; 95% CI, 0.18–3.1) but not on PTB < 37 weeks (15 vs. 13%; RR, 1.2; 95% CI, 0.39–3.5).

Conclusion: In women with a short cervix, who are otherwise low risk, we could not show a significant benefit of progesterone in reducing adverse neonatal outcome and PTB.

Journal Article Type Article
Online Publication Date Mar 4, 2015
Publication Date 2015
Deposit Date Aug 6, 2023
Journal American Journal of Perinatology
Print ISSN 0735-1631
Electronic ISSN 1098-8785
Publisher Thieme Publishing
Peer Reviewed Peer Reviewed
Volume 32
Issue 10
Pages 993-1000
DOI https://doi.org/10.1055/s-0035-1547327
Keywords Obstetrics and Gynecology; Pediatrics, Perinatology and Child Health
Public URL https://nottingham-repository.worktribe.com/output/23513645